Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
A head-to-head of Alnylam Pharmaceuticals, Inc. (ALNY) and Incyte Corporation (INCY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ALNY | INCY |
|---|---|---|
| Market Cap | $41.87B | $19.57B |
| P/E (TTM) | 79.94 | 13.84 |
| Forward P/E | 21.24 | 10.52 |
| P/S | 9.77 | 3.55 |
| P/B | 36.31 | 3.48 |
| EV/EBITDA | 44.53 | 9.71 |
| Dividend Yield | — | — |
| Profit Margin | 13.46% | 26.71% |
| Gross Margin | 81.64% | 92.76% |
| Operating Margin | 13.51% | 26.12% |
| Revenue Growth (YoY) | +96.43% | +20.87% |
| FCF Yield | 1.54% | 7.47% |
| Debt / Equity | 93.86 | 0.70 |
| Current Ratio | 3.13 | 3.68 |
Share:
Compare Alnylam Pharmaceuticals, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.